Amicus Therapeutics (FOLD) Competitors $7.99 -0.03 (-0.37%) Closing price 04:00 PM EasternExtended Trading$7.94 -0.06 (-0.69%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. IONS, MDGL, HALO, RGEN, ALKS, LGND, BCRX, MNKD, CLDX, and INVAShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Its Competitors Ionis Pharmaceuticals Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals MannKind Celldex Therapeutics Innoviva Ionis Pharmaceuticals (NASDAQ:IONS) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk and volatility, IONS or FOLD? Ionis Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Which has preferable valuation & earnings, IONS or FOLD? Amicus Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$705M14.28-$453.90M-$1.84-34.33Amicus Therapeutics$528.29M4.66-$56.11M-$0.12-66.58 Does the media prefer IONS or FOLD? In the previous week, Ionis Pharmaceuticals had 12 more articles in the media than Amicus Therapeutics. MarketBeat recorded 23 mentions for Ionis Pharmaceuticals and 11 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.28 beat Ionis Pharmaceuticals' score of 0.83 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IONS or FOLD? Ionis Pharmaceuticals currently has a consensus target price of $67.88, suggesting a potential upside of 7.47%. Amicus Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 100.25%. Given Amicus Therapeutics' higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.81Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Do insiders and institutionals hold more shares of IONS or FOLD? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.6% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is IONS or FOLD more profitable? Amicus Therapeutics has a net margin of -6.67% compared to Ionis Pharmaceuticals' net margin of -28.25%. Amicus Therapeutics' return on equity of -5.07% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-28.25% -45.29% -8.99% Amicus Therapeutics -6.67%-5.07%-1.23% SummaryIonis Pharmaceuticals beats Amicus Therapeutics on 9 of the 17 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.47B$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-66.5821.1774.5225.93Price / Sales4.66473.02539.62123.65Price / CashN/A46.6837.5660.44Price / Book12.299.6112.166.29Net Income-$56.11M-$53.29M$3.28B$270.77M7 Day PerformanceN/A0.29%0.98%3.36%1 Month Performance14.47%8.91%7.20%6.41%1 Year Performance-29.17%13.14%63.06%28.26% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics3.9693 of 5 stars$7.99-0.4%$16.00+100.3%-28.8%$2.47B$528.29M-66.58480Positive NewsIONSIonis Pharmaceuticals3.673 of 5 stars$61.00-0.4%$67.88+11.3%+50.6%$9.76B$944.05M-33.151,069Insider TradeMDGLMadrigal Pharmaceuticals4.3087 of 5 stars$453.80+4.8%$471.13+3.8%+88.6%$9.61B$180.13M-35.3290Positive NewsAnalyst ForecastInsider TradeHALOHalozyme Therapeutics4.567 of 5 stars$75.85+1.2%$67.11-11.5%+30.5%$8.76B$1.02B17.36390Positive NewsInsider TradeRGENRepligen4.8942 of 5 stars$120.70-3.1%$169.55+40.5%-16.7%$7.01B$673.96M-482.781,778Positive NewsAnalyst ForecastALKSAlkermes4.5526 of 5 stars$28.45-5.0%$41.31+45.2%+4.3%$4.94B$1.56B13.681,800Trending NewsAnalyst ForecastHigh Trading VolumeLGNDLigand Pharmaceuticals4.2328 of 5 stars$165.86-0.5%$176.50+6.4%+62.1%$3.27B$187.58M-41.4780Short Interest ↑BCRXBioCryst Pharmaceuticals4.2641 of 5 stars$8.19-1.0%$16.70+103.9%+4.4%$1.74B$450.71M-45.50530Positive NewsMNKDMannKind4.418 of 5 stars$5.57+0.5%$10.71+92.4%-11.6%$1.70B$285.50M50.64400Positive NewsShort Interest ↓CLDXCelldex Therapeutics2.3847 of 5 stars$23.40+2.3%$46.67+99.4%-39.5%$1.52B$7.02M-7.77150Positive NewsINVAInnoviva4.8913 of 5 stars$20.46-0.1%$42.75+108.9%+0.2%$1.29B$358.71M66.00100Positive NewsShort Interest ↓ Related Companies and Tools Related Companies IONS Alternatives MDGL Alternatives HALO Alternatives RGEN Alternatives ALKS Alternatives LGND Alternatives BCRX Alternatives MNKD Alternatives CLDX Alternatives INVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
